US2023112863A1PendingUtilityA1

IL-1 Binding Proteins

82
Assignee: ABBVIE INCPriority: May 14, 2010Filed: Apr 29, 2022Published: Apr 13, 2023
Est. expiryMay 14, 2030(~3.8 yrs left)· nominal 20-yr term from priority
A61P 31/14A61P 15/02A61P 37/02A61P 31/20A61P 37/08C07K 2317/64A61P 17/00C07K 2317/76A61P 43/00A61K 38/00A61P 33/02A61P 15/08C07K 2317/56A61K 9/007A61P 9/10A61P 17/04C07K 2317/31A61K 39/3955A61P 31/00A61P 35/02A61P 3/00A61P 9/04A61P 5/18A61P 31/08A61P 27/14A61P 7/02A61P 1/14A61P 7/08A61P 11/06A61K 9/006A61P 9/00A61P 11/00A61K 9/0053Y02A50/30A61P 25/14A61K 9/0034C07K 2317/33A61P 31/16G01N 33/6869A61P 25/18G01N 2333/545A61P 25/06A61P 39/02A61P 25/24A61K 45/06G01N 2800/00C07K 14/545A61P 1/18C07K 16/245A61K 2039/505A61P 9/12A61P 21/04A61P 19/02A61K 47/6879A61P 17/08A61P 11/16A61P 1/00A61K 9/0019A61P 33/06A61P 31/10A61P 9/06A61P 3/10A61P 3/08A61P 37/04A61P 19/10A61P 25/30C07K 2317/35C07K 2317/92A61P 31/04A61P 37/06A61P 35/00A61P 21/02A61P 11/04A61P 5/48C07K 2317/565A61P 17/14A61P 5/14A61P 33/00C07K 16/468A61K 9/0085A61P 25/04C07K 2317/24A61P 9/14A61P 7/10A61P 31/06A61P 17/02A61P 25/32A61P 1/04A61P 19/06A61P 7/04A61P 15/10A61P 13/12A61P 25/00A61P 31/18A61P 37/00A61P 3/14A61P 29/00A61K 9/0014A61P 25/22A61P 7/06A61P 13/08A61P 13/02A61K 9/0043A61K 9/0031A61P 25/28A61P 27/02A61P 21/00A61P 31/12A61P 1/16A61P 5/00A61P 17/06A61P 9/08A61P 11/02A61P 5/16A61P 19/00A61P 5/50A61P 33/08A61P 25/16A61P 3/02A61P 3/06
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

Claims

exact text as granted — not AI-modified
1 .- 122 . (canceled) 
     
     
         123 . A kit for assaying a test sample for the presence, amount or concentration of an analyte (or a fragment thereof) in a test sample, comprising:
 at least one component for assaying the test sample for IL-1β (or a fragment thereof); and   instructions for assaying the test sample for the analyte (or a fragment thereof), wherein the at least one component for assaying the test sample for the analyte (or a fragment thereof) comprises a binding protein comprising:   an antigen binding domain, said binding protein capable of binding human IL-10, said antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, as defined below:   
       
         
           
                 
               
                   CDR-H1: X 1 -Y-D-M-S (SEQ ID NO: 190), wherein; 
                 
                   X 1  is K or R; 
                 
                   CDR-H2: Y-X 2 -S-X 4 -G-G-X 7 -G-T-Y-Y-P-D-X 14 -X 15 -K-G 
                 
                   (SEQ ID NO: 191), wherein; 
                 
                   X 2  is I or V; 
                 
                   X 4  is S or H; 
                 
                   X 7  is G or A; 
                 
                   X 14  is T or S; and 
                 
                   X 15  is V or A; 
                 
                     
                 
                   CDR-H3: G-G-V-X 4 -K-G-X 7 -F-D-X 10  (SEQ ID NO: 192), 
                 
                   wherein; 
                 
                   X 4  is T or Y; 
                 
                   X 7  is Y or C; and 
                 
                   X 10  is V, E, L, M, Q, or Y; 
                 
                     
                 
                   CDR-L1: R-A-S-G-N-I-X 7 -X 8 -X 9 -L-X 11  (SEQ ID NO: 193), 
                 
                   wherein; 
                 
                   X 7  is H, Y, or W; 
                 
                   X 8  is N, G, T, Q, E, H, D, or K; 
                 
                   X 9  is Y or W; and 
                 
                   X 11  is T, A, or N; 
                 
                     
                 
                   CDR-L2: X 1 -A-K-X 4 -L-X 6 -X 7  (SEQ ID NO: 194), 
                 
                   wherein; 
                 
                   X 1  is N, Q, or D; 
                 
                   X 4  is T, N, I, E, or S; 
                 
                   X 6  is A, M, or E; and 
                 
                   X 7  is D, E, S, or A; 
                 
                   and 
                 
                     
                 
                   CDR-L3: Q-X 2 -F-W-X 5 -X 6 -P-X 8 -X 9  (SEQ ID NO: 195) 
                 
                   wherein; 
                 
                   X 2  is H or Q; 
                 
                   X 5  is S, N, T, K, R, or M; 
                 
                   X 6  is I or L; 
                 
                   X 8  is Y or A; and 
                 
                   X 9  is T, I, and N 
                 
                     
                 
                   except that: 
                 
                   CDR-H2 cannot be Y-I-S-S-G-G-G-G-T-Y-Y-P-D-T-V-K-G 
                 
                   (SEQ ID NO: 18); 
                 
                     
                 
                   CDR-H3 cannot be G-G-V-T-K-G-Y-F-D-V 
                 
                   (SEQ ID NO: 19); 
                 
                     
                 
                   CDR-L1 cannot be R-A-S-G-N-I-H-N-Y-L-T 
                 
                   (SEQ ID NO: 20); 
                 
                     
                 
                   CDR-L2 cannot be N-A-K-T-L-A-D (SEQ ID NO: 21); 
                 
                   and 
                 
                     
                 
                   CDR-L3 cannot be Q-H-F-W-S-I-P-Y-T 
                 
                   (SEQ ID NO: 22).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.